Acrivon Therapeutics (NASDAQ:ACRV) CFO Acquires $15,014.40 in Stock

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) CFO Adam Levy bought 8,832 shares of Acrivon Therapeutics stock in a transaction on Wednesday, January 14th. The shares were purchased at an average cost of $1.70 per share, with a total value of $15,014.40. Following the acquisition, the chief financial officer directly owned 20,983 shares of the company’s stock, valued at approximately $35,671.10. The trade was a 72.69% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Acrivon Therapeutics Price Performance

Shares of NASDAQ:ACRV traded up $0.11 during midday trading on Friday, hitting $1.98. The company had a trading volume of 1,997,999 shares, compared to its average volume of 5,854,625. The business’s 50-day simple moving average is $2.30 and its 200-day simple moving average is $1.82. The stock has a market cap of $62.49 million, a price-to-earnings ratio of -0.93 and a beta of 1.73. Acrivon Therapeutics, Inc. has a twelve month low of $1.05 and a twelve month high of $8.00.

Acrivon Therapeutics (NASDAQ:ACRV) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.10. As a group, sell-side analysts forecast that Acrivon Therapeutics, Inc. will post -2.49 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ACRV. Quadrature Capital Ltd purchased a new position in Acrivon Therapeutics in the second quarter valued at about $26,000. Focus Partners Wealth acquired a new stake in Acrivon Therapeutics during the 3rd quarter valued at approximately $36,000. Invesco Ltd. bought a new stake in shares of Acrivon Therapeutics in the first quarter worth $72,000. Algert Global LLC bought a new position in shares of Acrivon Therapeutics during the third quarter worth about $81,000. Finally, XTX Topco Ltd acquired a new position in shares of Acrivon Therapeutics in the 2nd quarter worth approximately $126,000. 71.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ACRV has been the topic of a number of analyst reports. Piper Sandler raised their price objective on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Friday, January 9th. HC Wainwright reiterated a “buy” rating and set a $19.00 price target on shares of Acrivon Therapeutics in a research note on Tuesday, November 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Acrivon Therapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen lowered Acrivon Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.